Metabolomics reveals gamma-glutamyl dipeptides as biomarkers for differentiation of liver diseases including hepatocellular carcinoma.

presented by Soga, T. et al.

• Sheet 1 :Results of metabome analysis of serum from healthy controls and patients with liver disease in the training.
• Sheet 2 Results of metabome analysis of serum from healthy controls and patients with liver disease in the validation cohort.
• Sheet 3 Concentrations of g-glutamyl dipeptides in sera from gastric cancer (GC) patients.
• Sheet 4 All data of metabolome analysis and clinical features in the training cohort.
• Sheet 5 All data of metabolome analysis and clinical features in the validation cohort.